PERSPECTA

News from every angle

Back to headlines

FDA Extends Review of Biogen's Alzheimer's Drug Leqembi

The U.S. Food and Drug Administration (FDA) has extended its review period for Biogen's Alzheimer's injection, Leqembi, delaying a decision on its approval.

PostShare

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.